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Abstract:  
 
Understanding the mechanisms of cell function and drug action is a major endeavor in 
the pharmaceutical industry. Drug effects are governed by the intrinsic properties of the 
drug (i.e., selectivity and potency) and the specific signaling transduction network of the 
host (i.e., normal vs. diseased cells). Here, we describe an unbiased, phosphoproteomic-
based approach to identify drug effects by monitoring drug-induced topology alterations. 
With the proposed method, drug effects are investigated under several conditions on a 
cell-type specific signaling network. First, starting with a generic pathway made of 
logical gates, we build a cell-type specific map by constraining it to fit 13 key 
phopshoprotein signals under 55 experimental cases. Fitting is performed via a 
formulation as an Integer Linear Program (ILP) and solution by standard ILP solvers; a 
procedure that drastically outperforms previous fitting schemes. Then, knowing the cell 
topology, we monitor the same key phopshoprotein signals under the presence of drug 
and cytokines and we re-optimize the specific map to reveal the drug-induced topology 
alterations. To prove our case, we make a pathway map for the hepatocytic cell line 
HepG2 and we evaluate the effects of 4 drugs: 3 selective inhibitors for the Epidermal 
Growth Factor Receptor (EGFR) and a non selective drug. We confirm effects easily 
predictable from the drugs’ main target (i.e. EGFR inhibitors blocks the EGFR pathway) 
but we also uncover unanticipated effects due to either drug promiscuity or the cell’s 
specific topology. An interesting finding is that the selective EGFR inhibitor Gefitinib is 
able to inhibit signaling downstream the Interleukin-1alpha (IL-1α) pathway; an effect 
that cannot be extracted from binding affinity based approaches. Our method represents 
an unbiased approach to identify drug effects on a small to medium size pathways and 
is scalable to larger topologies with any type of signaling perturbations (small molecules, 
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RNAi etc). The method is a step towards a better picture of drug effects in pathways, 
the cornerstone in identifying the mechanisms of drug efficacy and toxicity.  
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Author Summary:  
Cells are complex functional units. Signal transduction refers to the underlying 
mechanism that regulates cell function and it is usually depicted on signaling pathways 
maps. Each cell type has distinct signaling transduction mechanisms and several 
diseases arise from alterations on the signaling pathways. Small-molecule inhibitors have 
immerged as novel pharmaceutical interventions that aim to block certain pathways in 
an effort to reverse the abnormal phenotype of the diseased cells. Despite that 
compounds have been well designed to hit certain molecules (i.e. targets), little is 
known on how they act on an “operative” signaling network. Here, we combine novel 
high throughput protein-signaling measurements and sophisticated computational 
techniques to evaluate drug effects on cells. Our approach comprises of two steps: build 
pathways that simulate cell function and identify drug-induced alterations of those 
pathways. We employed our approach to evaluate the effects of 4 drugs on a cancer 
hepatocytic cell type.  We were able to confirm the main target of the drugs but also 
uncover unknown off-target effects. By understanding the drug effects in normal and 
diseased cells we can provide important information for the analysis of clinical outcomes 
in order to improve drug efficacy and safety. 
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Introduction 
Target-based drug discovery is a predominant focus of the pharmaceutical 
industry. The primary objective is to selectively target protein(s) within diseased cells in 
order to ameliorate an undesired phenotype, e.g., unrestrained cell proliferation or 
inflammatory cytokine release.  Ideally, other pathways within the diseased cells, as well 
as similar phenotypes in other cell types, should remain unaffected by the therapeutic 
approach. However, despite the plethora of new potential targets immerged from the 
sequencing of the human genome, rather few have proven effective in the clinic [1]. A 
major limitation is the inability to understand the mechanisms or drug actions either due 
to the complex signaling transduction networks of cells or due to the complicated profile 
of drug potency and selectivity.  
Finding drug’s targets is traditionally based on high-throughput in vitro assays 
using recombinant enzymes or protein fragments [2]. The main goal is to characterize 
the drug’s biochemical activity (binding affinities that describe potency and selectivity) 
and depict them in drug-interaction maps [3]. In most cases, once the target(s) is 
known, the in vivo effect on the signaling pathway is validated by measuring the drug’s 
efficiency to inhibit the activity (usually measured as phosphorylation level [4]) of the 
downstream protein. However, beyond that measurement, little is know on how the rest 
of the signaling network is affected. In addition, in vivo drug effects can hardly be 
calculated from in vitro assays for several reasons: most kinase inhibitors are 
promiscuous [5], there is discrepancy between in vivo and in vitro binding affinities of 
drugs [6], and there is an additional discrepancy between in vivo binding affinities and 
in vivo inhibitor activity for the phosphorylation of downstream signals.  
To address drug effects in more physiological conditions, novel genomic and 
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proteomic tools have recently been developed [7]. In the genomic arena, large-scale 
mRNA analysis (e.g., [8,9]) enhanced by computational approaches for drug target 
deconvolution (e.g., [10,11]) have been developed. Despite the holistic advantages that 
genomic approaches have to offer, proteomic-based discovery is a step closer to the 
function of the cell. Towards this goal, affinity chromatography offers a viable strategy 
for in-vivo target identification. This approach utilizes a solid support linked to a bait 
(usually the drug) to enrich for cellular binding proteins that are identified by mass 
spectrometry (MS) [12]. However, such experiments usually require large amounts of 
starting protein, are biased toward more abundant proteins, and result in several hits 
due to nonspecific interactions [13,14]. In order to circumvent the non-specific 
interaction problem, another bait-based strategy uses quantitative MS with “dirty” 
inhibitors for baits to immobilize the kinome [15,16]. While this approach significantly 
reduces the non-specific interaction problem, it also limits the target-searching space to 
those kinases with the highest affinity to the bait.  More recently, quantitative MS-based 
proteomics using SILAC technology [14] extends the search space to all targets that do 
not bind covalently to the drug. However, incorporation of the SILAC’s isotopes requires 
5 population doublings and thus, excludes the application on primary cells with limited 
replication capabilities. Taken together, all techniques listed above can -in the best case 
scenario- list the affinities of all targets to the drug but no information is provided 
whether this binding affinity is capable of inhibiting the transmission of the signal to the 
downstream protein or how those preferential bindings can collectively affect the 
signaling network of the cell.  
Here, we describe a significantly different approach to identify drug effects 
where drugs are evaluated by the alterations they cause on signaling pathways. Instead 
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of identifying binding partners, we monitor pathway alterations by following key 
phosphorylation events under several treatments with cytokines. The workflow is 
presented in Figure 1. On the experimental front, using bead-based multiplexed assays 
[17], we measure 13 key phosphorylation events under more than 50 different 
conditions generated by the combinatorial treatment of stimuli and selective inhibitors. 
Based on the signaling response and an a-priori set of possible reactions (i.e. generic 
pathway), we create a cell-type specific pathway using an efficient optimization 
formulation known as Integer Linear Programming (ILP). This approach builds upon the 
Boolean optimization approach proposed in [18]. The ILP is solved using standard 
commercial software packages to guaranteed global optimality (within a user-defined, 
numerically small tolerance). To evaluate drug effects, we subject the cells with the 
same stimuli in the presence of drugs and we tract the alterations of the same key 
phosphorylation events. Then, we reapply the ILP formulation without a-priori 
assumption of the drug target, and we monitor the changes in the pathway topology 
with and without drug presence. To demonstrate our approach, we construct a generic 
map and optimize it to fit the phosphoproteomic data of the transformed hepatocytic cell 
lines HepG2. Then, we identify the effects of four drugs: the dual EGFR/ErbB-2 inhibitor 
Lapatinib [19], two potent EGFR kinase inhibitors Erlotinib [20] and Gefitinib [21], and 
the “dirty” Raf kinase inhibitor Sorafenib [22]. When our method is applied on those 4 
drugs we find their main target effect and we also uncover several unknown but equally 
active off-target effects. In the case of Gefitinib, we find a surprising inhibition of cJUN 
in the IL1α pathway. 
In contrast to previously developed techniques, our method is based on the 
actual effect on phosphorylation events carefully spread into the signaling network. 
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Theoretically, it can be applied on any type of intracellular perturbations such as ATP-
based and allosteric kinase inhibitors, RNAi, shRNA etc. On the computational front, our 
ILP-based approach performs faster and more efficient than current algorithms for 
pathway optimization [18] and can identify the main drug effects as well as unknown 
off-target effects in areas of pathways constrained between the activated receptors and 
the measured phosphorylated proteins. Our fast and unbiased characterization of modes 
of drug actions can shed a light into the potential mechanisms drug’s efficacy and 
toxicity.  
 
Results 
Construction of phosphoproteomic datasets 
 High-throughput bead-based ELISA-type experiments using xMAP technology 
(Luminex, Texas, USA) are performed as briefly described in the Materials and Methods 
section and in [17]. We create two datasets: one for the construction of cell-type 
specific topology and another for the identification of the mechanisms of drug actions. 
To do that, HepG2s are stimulated in 10 different ways with combinatorial treatments 
with a diverse set of 5 ligands  (TNFα, IL1α, HGF, INS, TGFα, and no stimuli) and either 
4 highly selective inhibitors (PI3K, MEK, p38, cMET, and no inhibitor) or 4 commercial 
drugs (EGFR inhibitors Lapatinib, Erlotinib and Gefitinib, and the “dirty” inhibitor 
Sorafenib) (Figure 1b and 1d). For the purpose of this paper, we refer to “inhibitors” as 
the compounds for which we know the target and we use them in a concentration 
capable to block ~95% of the downstream protein. Conversely, we refer to “drugs” as 
the compounds for which we assume no a-priori knowledge of their target. For each 
combination of cytokine and drug/inhibitor we collect cell lysates at 5 and 25 minutes. 
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The two time points are pooled together in 1:1 ratio and the mixed lysates are used as 
an indicator of the “average early signaling response”. For each treatment we measure 
13 protein phosphorylations that we consider “key protein activities” (raw data in Figure 
S1). The key phosphorylation signals (listed in Materials and Methods) are chosen based 
on the availability of the reagents and quality controls performed at the early phases of 
the experimental setup [17]. The raw data (arbitrary fluorescent intensities) are 
normalized to fit logic models as described in [18] using a non-linear transformation that 
converts raw data into values between 0 and 1 where 1 corresponds to the fully 
activated state and 0 to no-activation. It has to be noted that logic-transformed data 
depends on what should be considered “protein activation” (transformed value >0.5), a 
criterion that is embedded in the transformation function and accounts for signal-to-
noise limits, saturation of the detection scheme, and eliminates biases that could have 
been introduced by the variability of antibody affinities [18].  
 
Generic pathway assembly and visualization 
The generic pathway map is constructed in the neighborhood of the 5 stimuli 
and the 13 measurements. The ubiquitous presence of conflicting reports on pathway 
maps and alternative protein names makes this step a highly nontrivial one. We 
explored several pathway databases including STKE, Pathway Interaction Database, 
KEGG, Pathway Commons, Ingenuity, and Pathway Studio [23,24]. Our limited 
intracellular protein coverage makes impractical the reduction of very large pathway 
datasets such as those found in Pathway Commons. Here, we create the initial topology 
from the union of canonical pathways found in Ingenuity (Redwood City, California) with 
subsequent manual curation. 
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A detailed description of Boolean representation of pathways can be found 
elsewhere [18,25-28]. In the present manuscript as opposed to [18], the connectivity in 
our pathway (Figure 2, left panel) is represented with OR gates and only few 
connections (represented with small black circles in Figure 2) require an AND gate. We 
are therefore not comparing OR vs. AND gates, but rather assuming our pathways to be 
'causal' graphs, and since there are a few AND gates we refer to it as Boolean model 
[29].  
 
Construction of cell-type specific pathway via ILP formulation  
The formulation for the optimal pathway identification is a 0-1 Integer Linear 
Program, i.e., an optimization problem with binary variables and linear constraints (see 
Materials and Methods). The optimizer, picks values for the decision variables, such that 
the logical constraints are satisfied and the objective(s) optimized. The primary objective 
is to find an optimal pathway, i.e., a pathway that best describes a set of 
phosphoproteomic data under a given model (e.g. Boolean). A secondary objective is 
that the pathway is as small as possible, i.e., has as few connections as possible, such 
that the best-possible fit of the experiments is maintained (see Materials and Methods).  
It is shown that some of the binary variables can be relaxed to continuous, without 
changing the feasible set. 
The ILP is solved with the state-of-the-art commercial code (CPLEX [30,31]) that 
guarantees minimal error between experimental data and the Boolean topology. The 
goodness of fit (percent error as described in Materials and Methods) was decreased 
from 36.7% on the generic map to 8.3% on the optimized map (Figure 2). The main 
source of error is the inability of TGFα to activate the IRS1_s (serine residue of IRS1) 
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(see the red background on the IRS1 row at the bottom panel of Figure 2). This is a 
result of the infeasibility of the generic pathway to satisfy the activation of IRS1_s in a 
TGFα/IL1α-dependant but HGF/INS-independent manner: TGFα activation of IRS1_s 
requires mTOR activation via AKT which the optimization algorithm removes to satisfy 
the inactivation IRS1_s by INS that shares the same path with TGFα. This example 
highlights the importance of multi-perturbations to better constrain the optimization 
formulation.  
Figure 2 shows the optimized topology of HepG2s. Our ILP formulation uses two 
subsequently-imposed objective functions to remove reactions that do not fit the 
experimental data. During the optimization of the first objective the ILP formulation (A) 
keeps reactions that lead to phosphorylations of the key proteins and (B) removes 
reactions that lead to false protein activations. An example of the first case is the Insulin 
(INS)-induced AKT activation that is maintained via the INS->IRb->IRS1t->PI3K-> 
PIP3->PDK1->AKT path (see INS to AKT path in Figure 2).  An example of a removed 
reaction is the TNFR->PI3K reaction which is removed because there is no TNFa induced 
AKT activation (see TNFR->PI3K->…->AKT in Figure 2).  During the optimization of the 
secondary objective (see Materials and Methods), several reactions with no evidence of 
their existence (no downstream measurements, or no stimuli) are removed. In this step, 
the overall goodness of fit is not improved, but the size of the topology is reduced. To 
illustrate this case, we add to the initial topology the receptor IL6R but the associated 
stimulus IL6 is not introduced on the experiments. After the secondary optimization, all 
downstream reactions of IL6 are removed because no data are present (see reaction 
arrows downstream for of IL6 in Figure 2). Similarly, all reactions downstream of the 
bottom-of-the-network key proteins are removed (e.g. CJUN->CFOS reaction in Figure 
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2). All those reactions might be present in reality and could have been kept if the 
secondary objective was not present. Here, we apply the secondary objective and follow 
a network trimming which removes all reactions that might be present in the cell but 
due to the lack of measured signals or experimental conditions cannot be verified. The 
resulting network is significantly smaller but contains only elements for which there are 
solid experimental evidence that explain the topology. 
To validate our model, we also examine three scenarios where we remove 20% 
of our experimental data, and then we try to predict them. Specifically, we create three 
training datasets, each time by removing all cases where one inhibitor is present (either 
MEKi, PI3Ki, or p38i) and then we calculate how well our ILP-optimized map can predict 
each of the inhibitor cases (see Figure S2). For the MEKi, PI3Ki, and p38i scenarios the 
goodness of fit is 8.22%, 9.46%, 7.05% respectively and our ILP-formulation converges 
on the same or slightly less optimal solutions compared to the solutions obtained when 
the whole dataset is used for training (4.47%, 7.76%, and 7.05% respectively) - See 
Figure S2. Note that the errors given refer only to the subset considered in each case, 
not the entire dataset. More extensive validations for Boolean-type models on similar 
phospho-proteomic dataset can also be found in Saez-Rodriguez et al. [18].     
 
Comparison with genetic algorithm 
In order to compare the ILP algorithm with the previously published genetic 
algorithm (GA) we use the same initial topology and the same normalized dataset [18].  
The two algorithms reached almost identical results (see Figure S3). For the ILP, the 
computational requirements are manageable, in the order of a few seconds (14.3 
seconds for this example) on an Quad Core Intel Xeon Processor E5405 (2.00GHz,2X6M 
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L2,1333) running Linux 2.6.25.20 (using only one core). In comparison, the same 
optimization problem using GA requires approximately 1 hour on a similar power 
computer. The optimal pathway furnished by the ILP matches all but 98 out of 880 
experimental data, as opposed to 110 mismatches in the topology furnished by the GA. 
It has to be noted that GA does not provide termination criteria, and it is conceivable 
that after even larger CPU times the GA would have achieved the same fit as the ILP. In 
contrast the deterministic solution of the ILP guarantees that an optimal fit (not 
necessarily unique) has been identified within a user-specified tolerance (10-3 in our 
case). In addition to the guaranteed optimal solution, commercial ILP solvers are fast, 
robust and reliable. Note that open-source ILP solvers also exist, but in our experience 
are not yet adequate. Note also that for larger network topologies, the differences in 
CPU time will become even more dramatic, rendering the GA intractable. 
The notable differences between the proposed method and the method used in 
[18] is mainly due to fundamental algorithmic differences: the technology behind 
deterministic ILP solvers (branch-and-bound, branch-and-cut) is more sophisticated than 
genetic algorithms, it employs the inherent linearity of the problem, and makes use of 
the good scalability of linear programs (sub-problems in branch-and-bound tree). In 
contrast, GA treats the model as a black-box and does not exploit the problem structure. 
Another point is that herein we used a well-established commercial solver, whereas 
Saez-Rodriguez et al. [18] used their own implementation of GA. Commercial 
deterministic ILP solvers, such as CPLEX, rely on several decades of research and 
development, and have extremely powerful features such as pre-processors and node 
selection heuristics. Thus, they typically become the default choice for ILPs. 
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Identifying drug effects via drug-induced topology alterations.   
 For the identification of the drug effects we make use of the second dataset in 
HepG2s where drugs are applied together with the same set of ligands. In this case, the 
ILP formulation is being used with the HepG2 specific topology (topology obtained from 
the previous step) and not the generic map. We also do not impose inhibitor constrains 
the way we do for pathway optimization (e.g., PI3K inhibitor blocks the signal 
downstream of PI3K) but we let the optimization algorithm decide which reaction(s) 
should be removed in order to fit the drug-induced data.  
The effect of Lapatinib (Figure 3a), the most selective and specific EGFR inhibitor 
[32], is the complete removal of the downstream reactions of the TGFa branch: TGFA-
>GRB2->SOS->RAS->PI3K and RAS->RAF1->MEK1/2->ERK1/2. This resulted from the 
fact that Lapatinib blocks the TGFα induced MEK1/2, ERK1/2, and AKT phosphosignals 
(Figure 3e). Note that the PI3K->…->AKT branch is not removed because it is being 
used by the HGF and INS path for the activation of AKT that cannot be blocked by 
Lapatinib (Figure 3e). 
Gefitinib, an EGFR tyrosine kinase inhibitor, alters the topology in a very similar 
pattern as Lapatinib, but, interestingly enough, it also results in the removal of the JNK -
> c-JUN branch (Figure 3b). Closer examination of the raw data (Figure 3f) shows a 
potent inhibition of IL1α− and (IL1 α+TGF α)-induced cJUN activity upon Gefitinib 
treatment. To follow up this interesting off-target effect, we did a dose-response 
experiment where Gefitinib shows that it can reduce the activation of cJUN signal 
induced by the IL1α stimuli (Figure 3i). We believe that the inhibition of cJUN is not due 
to the binding of Gefitinib in the upstream molecule JNK but a collective effect of 
signaling inhibitions in several species that take part in the path between IL1α and 
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cJUN. For this reason, a fitting with a typical dose response curve has been avoided and 
a simple linear equation has been used instead (Figure 3i). Erlotinib, another EGFR 
inhibitor, has the same effects as Gefitinib (Figure 3c) but at the same time shows an 
effect in the TRAF6->MAP3k7 reaction. This effects is probably because IκB-α is 
inhibited in an IL1α-dependent but TNFα-independent manner (see IκB-α signals upon 
IL1α and TNFα stimuli in Figure S1); the only way for the ILP to satisfy this behavior is 
to remove the transmission of signal before the merging of TNFα and IL1α paths which 
can be done through the TRAF6->MAP3K reaction.  
 The “dirty” Raf inhibitor Sorafenib shows a very different profile: it also blocks 
the JNK->c-JUN branch (Figure 3d) and in addition affects the p38 path (see complete 
HSP27 inhibition upon IL1a treatment in Figure 3h). An interesting observation is that 
network optimization does not remove the RAF->ERK1/2 reaction despite the fact that 
RAF is the main target of Sorafenib. Close inspection of the data shows that Sorafenib 
reduces but does not block the MEK1 phosphorylation (see MEK phosphorylation in 
Figure 3h). This is in agreement with previous published results where Sorafenib does 
not inhibit activation of the RAF/MEK/ERK pathway in all human tumor cell lines [33] a 
finding that highlights the importance of in-vivo assays for the quantification of drug 
effects.    
 
Discussion 
 In this article, we present an unbiased phosphoproteomic-based approach and 
an optimization formulation to construct cell-type specific pathways and to identify drug 
effects on those pathways. For the pathway construction, we track 13 key 
phopshorylation signals in 55 different conditions generated by the combinatorial 
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treatment of stimuli and inhibitors. Using Integer Linear Programming (ILP) for pathway 
optimization we took a generic network of 74 proteins and 105 reactions and construct a 
cell-type specific network of 49 proteins and 44 reactions that spans between the 5 
stimuli and the 13 measured phosphorylated proteins. In this network, we monitor 4 
cases of drug-induced pathway alterations using a similar computational scheme.  
In comparison to all other protein-based target identification approaches, our 
method is not based on measurements of drug affinities either by in vitro or in vivo 
assays.  Instead, we use an “operative” signaling network and rely on key 
phosphorylation events and a-priori knowledge of possible connections to reveal the 
topology and monitor its alterations under the presence of the drug. Thus, our method 
is expandable to any type of intracellular perturbations such as ATP-based and allosteric 
inhibitors, RNAi, shRNA etc. Since no bait or MS is required, we have simple ELISA-type 
experimental procedure with minimal requirements of cell starting protein (~30,000 cells 
per condition), without affinity immobilizations, protein fractionations, or carefully 
optimized wash conditions. With our current semi-automated procedures in our lab 
(robotic liquid handlers), we can achieve total experimental and computational time for 
a similar size experiment in less than a week. On the other side, our approach can only 
detect signaling alterations in topologies bounded between the applied stimuli and the 
measured phosphorylated proteins and it misses off-target effects outside the 
constructed network. The expansion of the constructed network depends primarily on 
three factors: highly curated generic topology, multiplex assay availability for “key” 
phosphorylation measurements, and experimental cost. We believe that the explosive 
growth of multiplexed phosphoproteomic assays, the rapid reduction of the cost per 
datapoint, and the significant improvement in quality of several pathways databases will 
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significantly increase the searching space for drug effects using our proposed 
methodology. However, our search space will always be significantly smaller compared 
to whole-genome based approaches [8-11] because it requires (a) the input of a generic 
pathway which is available only in well-studied pathways and (b) good quality antibodies 
for the detection scheme.  By merging our phosphoproteomic method with genome-
wide screening techniques, we might be able to combine the strengths of both 
approaches and increase the searching space for off-target drug effects.   
An important aspect of the current approach is the construction of pathway 
maps. Pathway construction is a major endeavor in biology and a variety of 
experimental [34-38] and computational approaches that span from data-driven 
methodologies (e.g., statistical, unsupervised machine learning) to topology-based 
methods (e.g., kinetic models based on ordinary differential equations-ODEs) [17,35,38-
41] have been developed. Our approach, which is based on Boolean (logical) modeling 
[26-28,42], represents a simplified topology-based method.  Compared to ODE-based 
methods, a logic model has limited abilities to model kinetic behavior [25] (especially 
when modeling feedback loops in single-step logic models) or even to model the protein 
activity in a continuous fashion. On the flip side, logic models do not require parameter 
estimation (sometimes ill-defined from lack of experimental data) and thus can be 
applied for the simulation of large topologies. A refinement of the model formalism into 
multistep logic [28], fuzzy logic [43], or ODE-based logic systems [44] may provide a 
more precise simulation of the activity and time-dependency of the signaling network. 
Taking into account the current limitations of experimental assays (throughput, 
sensitivity, reliability, cost) we believe that Boolean modeling is the method of choice 
with high predictive power when large topologies are studied.   
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Optimizing pathway topologies is a relatively new approach for the construction 
of cell-type specific pathways. Using Boolean topology and Genetic Algorithm (GA) for 
an optimization scheme, Saez-Rodriguez et al. [18] are able to fit a generic map to cell-
type specific map from phosphoprotein data. Here we present an alternative method of 
optimal pathway identification based on ILP. Compared to GA, our algorithm gives 
guaranteed globally optimized map (the solution identified is guaranteed to be no worse 
than 0.001 than any other possible solution). Additionally, the computational cost has 
cut down dramatically and allows pathway optimization with ~70 species to be 
performed on a desktop computer in a matter of few seconds. Due to minimal 
computational requirements ILP can be used for the construction of large pathways 
(assuming that experimental capabilities can by matched) and for the exploration of 
alternative reactions beyond the generic topology to further improve the optimal fit. 
However, several factors should be addressed before expanding our formulation to 
larger topologies. Although our formulation is able to identify a globally optimal solution, 
additional optimal solutions might exist [18] in the same generic network and further 
more solutions might arise when the optimization formulation is relaxed. Larger and 
more interconnected networks increase the number of solutions that are equally (or 
near equally) optimal. A possible way to circumvent this problem is to reduce our 
network using techniques that have been described previously in graph theory or in 
[18]. Being aware of those limitations in the present manuscript we described a “simple” 
and not highly interconnected network in order to minimize redundancy of solutions. To 
address the issue of finding a both unique and optimal solution we are currently working 
on two complementary approaches: (a) instructing the ILP solver to furnish a pool of 
near-optimal solutions and (b) devising “clever stimulations” by taking into account 
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experimental limitations (i.e., combination of inhibitors, stimuli, and key protein 
measurements) that maximally constrains the optimization scheme and gives smaller 
number of unique solutions.  
When applied in HepG2s, our approach identifies both known and unanticipated 
results. As a positive control, it removes the TGFα branch upon EGRF drug treatments. 
Another easily understandable effect is Sorafenib’s inhibition of the pathway 
downstream of p38 which can be explained by the drug’s target affinity to p38α and 
p38β [32,45]. A surprising effect is the removal of the JNK->cJUN reaction under the 
influence 3 out of 4 cancer drugs Erlotinib, Gefitinib and Sorafenib. Interestingly, kinase 
profiles of those drugs [32] shows no medium or high affinity for the directly upstream 
JNK1/2 kinases. Despite that, Gefitinib shows a significant reduction of the cJUN activity 
upon IL1a treatment. A possible explanation is that the signaling propagation can 
collectively be attenuated from the low or medium off-target inhibitions of several 
kinases upstream of JNK and cJUN. This also might explain the inhibition curve in Figure 
3i, where Gefitinib inhibition of cJUN activation does not follow a typical dose-response 
curve. In this context, sensitivity analysis in ODE-based pathway models [46] have 
shown that slight changes of reaction constants can have significant attenuations on 
protein activities several steps downstream the network and thus inhibitory curves 
cannot be simulated by simplified dose-response models. Our findings also highlight a 
unique feature of our approach: we find effects of drug’s promiscuity that cannot be 
identified by the direct binding of the drug to the upstream target but are the result of a 
collective effect of drug’s interactions with several upstream molecules. Bait-based 
analysis cannot reveal those effects since there is no binding involved between the drug 
and the protein.   
 20
Understanding the interplay between cell function and drug action is a major 
endeavor in the pharmaceutical industry. Here, we provided a methodology to construct 
cell type specific maps and identify drug effects on those maps. Our ILP formulation was 
able to build the best possible topology from a set of a-priori determined reactions and 
choose those, where their presence is confirmed from high throughput phosphoprotein 
data. Since phosphorylation events are the ultimate reporters of protein/drug function 
the use of high-throughput phosphoproteomic datasets gave an advantage in data 
quality for modeling signaling network. We believe our approach complements standard 
biochemical drug profiling assays and sheds new light into the discovery of possible 
mechanisms for drug’s efficacy and toxicity. 
 
Materials and Methods 
Experimental procedure: Phosphoprotein dataset 
 HepG2 cells were purchased from ATCC (Manassas, VA), and seeded on 96-well 
plates coated with collagen type I-coated (BD Biosciences, Franklin Lakes, NJ) at 
30,000 cells/well in DME medium containing 10% Fetal Bovine Serum (FBS). The 
following morning, cells were starved for 4 hours and treated with inhibitors and/or drugs. 
Kinase inhibitors were used at concentrations sufficient to inhibit at least 95% the 
phosphorylation of the nominal target as determined by dose-response assays 
(presented in [17]). AKT was chosen as the nominal target for Lapatinib, Erlotinib, and 
Gefitinib. The following saturated concentrations were used: p38 (PHA818637, 20 nM), 
MEK (PD325901, 100 nM) and cMET (JNJ38877605, 1μM), PI3K (PI-103, 10 μM), 
Lapatinib at 3uM [47], Erlotinib at 1 uM [47], Gefitinib at 3uM [47], and Sorafenib at 3 
uM (based on its inhibitory activity on ERK1/2 phosphorylation [33]). Following 
incubation for 45 minutes with inhibitors and/or drugs cells were treated with saturated 
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levels of 5 ligands: Tumor Necrosis Factor alpha (TNFα) at 100ng/ml, Interleukin 1 alpha 
(IL1α) at 10ng/ml, Insulin (INS) at 2uM, Transforming Growth Factor (TGFα) at 
100ng/ml, and Hepatocytes Growth Factor (HGF) at 100 ng/ml. Each ligand was added 
alone or in pairs and cell lysates were collected at 0, 5, and 25 minutes following the 
cytokine stimulation. The 5 and 25 minutes lysates were mixed together in 1:1 ratio and 
the mixed lysate was measured as an indicator of the “average early signaling 
response”. The 5 and 25 minute time points were identified in a preliminary experiment 
as the optimal time points that maximally captured early phosphorylation activities [17].  
A major improvement in the present dataset as compared to [17] was the “in-
vitro” averaging of the signals from 5 and 25 minutes rather than “in-silico” averaging 
(i.e., first both time points are measured, then we take the average). Three are the 
main advantages using such approach: 1) two signals are used instead of one and thus 
very early signalling responses can be captured, 2) the experimental cost is reduced by 
50% (or more for averaging multiple time points), and 3) we achieved the averaging of 
some signals that could not be measured independently because their “active” state is 
reaching the saturation limits of our measuring instrument.  
From each lysate we measured 13 phosphorylation activities that we considered 
“key phosphorylation events” using a Luminex 200 system (Luminex Corp, Austin, TX). 
The 13-plex phospho-protein bead set from Bio-Rad was used to assay p70S6K 
(Thr421/Ser424), CREB (Ser133), p38 (Thr180/Tyr182), MEK1 (Ser217/Ser221), JNK 
(Thr183/Tyr185), HSP27 (Ser78), ERK1/2 (Thr202/Tyr204, Thr185/Tyr187), c-JUN 
(Ser63), IRS-1 (Ser636/Ser639), IκB-α (Ser32/Ser36), Histone H3 (Ser10), Akt (Ser473), 
and IR-β (Tyr1146). Data were normalized and plotted using with DataRail [48]. For the 
construction of the dose response curve in Figure 3i, HepG2 were starved for 4 hours 
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and then incubated with Gefitinib (from 20uM down to 27nM – 3 fold dilution) for 45 
minutes followed by incubation with IL1α at 10ng/ml final concentration for 30 minutes. 
Duplicate lysates were analyzed using the c-JUN (Ser63) beads in the Luminex 200 
system. 
 
Computational procedure: ILP formulation  
Here, we describe how the Boolean model described in [18] can be reformulated 
as an ILP. Note that such a transformation was recently performed for a different 
problem, namely the satisfiability, by [49]. A pathway is defined as a set of reactions 
rni ,1,= K  and species snj ,1,= K . Each reaction has three corresponding index sets, 
namely the index set of signaling molecules iR , inhibitors iI , and “products” iP  
(“product” can also correspond to the phosphorylation level of the protein). These sets 
are all subsets of the species index set ( },{1,,, siii nK⊂PIR ). Typically, these subsets 
have very small cardinality (few species), e.g., 0,1,2|=| iR ; 0,1|=| iI ; 1,2|=| iP ; 
1,2|=||| ii IR + . A reaction takes place if and only if all reagents and no inhibitors are 
present. If a reaction takes place, all products are formed. Note that reactions without 
products as well as reactions with neither reagents nor inhibitors will be excluded here. 
While typically the set of species is known, the set of reactions is not known. 
Rather, only a superset of potential reactions is postulated. The goal of the proposed 
formulation is to find an optimal (in some sense) set of reactions out of such a superset. 
To that extent binary variables iy  are introduced, indicating if a reaction is possible or 
not ( 0=iy  connection not present, 1=iy  connection present). 
A set of experiments is performed, indexed by the superscript enk ,1,= K . In 
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each experiment a subset of species is introduced to the system and another subset is 
excluded from the system. These are summarized by the index sets ,1kM  and ,0kM  
respectively (two for each experiment). In the proposed formulation, constants are 
introduced for all such species, respectively 1=kjx  and 0=
k
jx . In the following it will be 
assumed that these species do not appear as products in any reaction; this assumption 
is not limiting, since in the experiments performed only extracellular species and 
inhibitors are manipulated. In the experiments a third subset of the species is measured 
(index set Mk,2) and for the remaining species no information is available. In the 
proposed formulation for each of the experiments and each such species a binary 
decision variable {0,1}∈kjx  is introduced indicating if the species j  is present ( 1=
k
jx ) 
or not ( 0=kjx ) in the experiment k  according to the model predictions. It is proved 
that in the absence of loops, [0,1]∈kjx  can be used for species that are not input 
species (see Text S4). This has some computational advantages.  
The last group of variables kiz  introduced indicate if reaction i  will take place 
( 1=kiz ) or not ( 0=
k
iz ) in the experiment k  according to the model predictions. It is 
proved that a real variable [0,1]∈kiz  can be used equivalently (see Text S4). This 
reformulation has some computational advantages. 
For the case that a species is measured, the measurement is defined as mkjx
, . 
For Boolean measurements {0,1}, ∈mkjx ; otherwise [0,1]
, ∈mkjx  (assuming a scaling as 
afforementioned). The primary objective function is formed aiming to minimize the 
weighted error between model predictions and measurements || ,
,
mk
j
k
j
k
jkj
xx −∑ α . The 
absolute value is reformulated as kj
mk
j
mk
j xxx )2(1
,,
−+ . It can be easily verified that for 
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binary kjx  and for {0,1}
, ∈mkjx  this reformulation is valid:   
    1.  0=kjx :  
 .||=|=|=0)2(1=)2(1 ,,,,,,, kj
mk
j
mk
j
mk
j
mk
j
mk
j
k
j
mk
j
mk
j xxxxxxxxx −−+−+  
    2.  1=kjx :  
 .||=|1=|1=1)2(1=)2(1 ,,,,,,, mkj
k
j
mk
j
mk
j
mk
j
mk
j
k
j
mk
j
mk
j xxxxxxxxx −−−−+−+  
Note also that alternative norms, such as least-squares errors, could be also 
used. The resulting optimization problem would still be an ILP, since the objective 
function involves only integer variables. For instance for the least-square error objective 
function the following linear reformulation is valid: 
 
(xjk-xjk,m)2 =(xjk)2 –(2 xjk xjk,m) +(xjk,m)2= (xjk)-(2 xjk xjk,m)+(xjk,m)2 
 
The secondary objective is to minimize the weighted number of possible 
reactions iii yβ∑ . In multiobjective optimization typically the concept of  Pareto-optimal 
or noninferior solution is introduced, i.e., a set of decision variable values, such that if 
one tries to improve one objective, another will be degraded [50]. The set of Pareto 
points forms the Pareto-optimal curve. Here, however, the primary objective is 
considered much more important than the secondary objective. Therefore, a single 
Pareto-optimal point is obtained, by first minimizing the primary objective and then the 
secondary objective by requiring that the former (more important) objectives are not 
worsened, see also [51-53]. 
The ILP proposed can be summarized as:    
 ( ) iir
n
i
n
k
k
j
mk
j
mk
j
k
j
jZyX
yxxx
e
k
βα ∑∑ ∑
= ∈
−+
1=1
,,
,,
;)2(1min
,2M
 (1) 
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 ,,1,=,s.t.
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 ier
k
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k
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k
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 ( ) ( ) .,1,=,,1,=,1 erkj
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IR
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i
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 .,1,=,,1,=,
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es
k
i
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k
j nknjzx KK
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∈
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P
 (8) 
 ,0,,1,=0,= ke
k
j jnkx M∈K  (9) 
 ,1,,1,=1,= ke
k
j jnkx M∈K  (10) 
 ,{0,1},{0,1},{0,1} rnenrnsnen ZyX ×× ∈∈∈  (11) 
where the objectives are separated by a semi-colon. Note that for the elements of the 
matrices X  and Z , the row index (experiment) is indicated as superscript, and the 
column index (species and reactions respectively) is indicated as subscript. 
In formulation (1)-(11) for the manipulated species binary decision variables 
along with the constraints (9) and (10) are introduced. This simplifies notation. In the 
implementation, these variables are replaced by constants. Alternatively the 
preprocessor of the optimization solver can be used to exclude these trivial variables. 
In the following the reasoning for the formulation is given. The first set of 
constraints, i.e., (2) allow the modeler to limit the combinations of connectivities 
considered. For instance, suppose that two reagents 1R , 2R  form a product P , but it 
is not known if both reagents (AND) or either (OR) are required. This can be modeled as 
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three potential reactions  
 PRRr →+ 21:1  
 PRr →1:2  
 ,2:3 PRr →  
 with the additional constraint that 1r  excludes 2r  and 3r , which can be modeled as 
two linear inequalities:  
 1
21
≤+ rr yy  
 1.
31
≤+ rr yy  
 
The constraints (3) indicate that a reaction can only take place if it is possible ( 1=iy ). 
This can be seen easily, since 0=iy , gives 0≤
k
iz  and together with {0,1}∈
k
iz  we 
obtain 0=kiz . Similarly, the constraints (4) and (5) ensure respectively that a reaction 
can only take place if all reagents and no inhibitors are present. If for instance a reagent 
is absent, 0=kiz  is enforced, and the other constraints are redundant. On the other 
hand, the constraints (6) enforce that if a reaction is possible, all reagents are present, 
and no inhibitors are present, then the reaction will take place ( 1=kiz ). 
The constraints (7) ensure that a species will be formed if some reaction in 
which it is a product occurs. Note that multiple reactions can give the same species; 
mathematically this will result in redundant constraints. In contrast, the constraints (8) 
enforce that a species will not be present if all reactions in which it appears as a product 
do not occur. Recall that manipulated species are not considered as products in 
reactions. Note also, that it would be possible to combine the constraints (7) into a 
single constraint for each species, e.g.,  
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but this would result in weaker LP-relaxations. Also the reformulation of kjx  to [0,1]  
would no longer be exact. 
In the present study, our ILP formulation was utilized in two different 
circumstances. For the creation of the cell-type specific pathway using combinations of 
inhibitors and stimuli our ILP formulation included 27887 constraints and 9732 variables. 
For each drug case, where the reduced and optimized pathway was utilized, we had 
2477 constraints and 947 variables.  
 
Computational procedure: Goodness of fit  
For the goodness of fit, we calculated the percentage error as: 
%100,
,
1=
⋅−=∑ mskjmkjsn
j
nxxError  
Note that for binary kjx  and ]0,1[
, ∈mkjx  the percentage error cannot be 0% 
even when there is no mismatch between model and experiment data. Another way to 
quantify the goodness of fit is by counting the number of mismatches: the cases where 
the rounded experimental value (0 or 1) is not the same with the computational value, 
or in other words, when experimental – computational error is more than 0.5.   
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FIGURES LEGENDS  
 
Figure 1. Experimental and computational workflow to assess drug effects. 
(a) A Boolean generic map is assempled from pathway databases and includes stimuli 
(green squares), key measured photeins (brown circles), and the neighboring proteins 
(yellow circles). (b) Cells are treated with a combination of cytokines and selective 
inhibitors (red circles) of known effects and an ILP formulation is used to fit the data to 
the Boolean pathway. (c) A cell-type specific pathway is constructed. (d) Cells are 
treated with a combination of cytokines and drugs –their effects are assumed unknown- 
and ILP is used for the second time to fit the drug-induced phosphorylation data. (e) 
Alterations of the the cell-type specific topology reveals drug effects (red arrows).  
 
Figure 2:  Cell type specific topology using Integer Linear Programming. The 
ILP algorithm is using a subset of postulated reactions denoted with arrows in a generic 
pathway (top right panel) to construct a HepG2 pathway map (bottom right panel). Gray 
triangles show phophoprotein activation level upon stimuli (columns in top and bottom 
panels) and inhibitors (subcolumns in top and bottom panels). Red background denotes 
an error between experimental and pathway-inferred responses. Generic topology can 
hardly represent the HepG2 signaling responses (top panel) and pathway optimization is 
critical to obtain a pathway topology that captures HepG2 function (bottom panel). 
Pathways are visualized using Cytoscape [54]. 
 
Figure 3:  Drug-induced pathway alterations. (a-d) Red arrows denote drug 
effects, i.e., reactions that are removed from the HepG2 topology by the ILP algorithm 
in order to fit the drug-altered phosphoprotein dataset. (e-h) Raw data that correspond 
to drug effects. Lines indicates the signal between 0 minutes (untreated) and “early 
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response” (average signal of 5 and 25 minutes post stimuli). (i) Off-target effect of 
Gefitinib. Dose response curve shows that the EGFR inhibitor reduces cJUN  activation 
upon IL1α treatment. R2 corresponds to linear fit. 



SUPPLEMENTARY FIGURE LEGENDS 
 
 
 
  Figure S1 - Raw data for the construction of the cell-type specific map and the 
evaluation of the drug effects. The signals in the Y-axis correspond to the 
measurements of the phosphorylated residues listed in Materials and Methods. Each 
column corresponds to cytokine or cytokine mix and each sub-column to the presence 
of an inhibitor or drug. The numbers to the left are the maximum values across all 
treatments measured as arbitrary fluorescent intensities.  
 
  Figure S2 - Model Validation. The first panel shows the optimization results when 
the full dataset (shown in Figure 2) has been used as training dataset. To validate our 
model, we created three subsets, in which 20% of our experimental cases are removed 
that correspond to the treatments with PI3K inhibitor (2nd panel), MEK inhibitor (3rd 
panel), and p38 inhibitor (bottom panel), and we trained our model against them. The 
data left out is then used as test dataset for prediction (see highlighted strips in each 
panel). The error of prediction of the test subsets (error = goodness of fit as describes 
in Materials and Methods) is shown on the right of each panel. 
 
  Figure S3 - Comparison between genetic algorithm and ILP. Both algorithms 
performed well and achieved very similar solutions. Red background denotes 
inconsistency between predicted values and experimental data: ILP matched all but 98 
out of 880 experimental data, as opposed to 110 mismatches in the topology furnished 
by the GA. The computational time for ILP was 14.3 sec as opposed to 
1approximately one hour for GA.  
 
  Text S4 - Equivalent reformulation as MILP  
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Supplemental material S4: Equivalent reformulation as MILP 
Recall that the ILP proposed is:    
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Relaxation of Z  
  We will argue that relaxing the Z  variables from binary to continuous gives an 
exact reformulation. It suffices to show that constraints (3)-(8) together with 
snenX {0,1}  and rny {0,1}  imply rnenZ {0,1} . 
 
Theorem 1  Replacing rnenZ {0,1}  by rnenZ [0,1]  is an exact reformulation, in the 
sense that any feasible point in the new program is also feasible in the original program.  
 Note that Theorem 1 is a special case of Theorem 2. Nevertheless it is given 
separately, because it does not require the assumption of acyclical graphs. Moreover, its 
proof is much simpler, and is used in the proof of Theorem 2. 
 
Proof. Take any snenX {0,1} , rny {0,1}  and rnenZ [0,1]  that satisfies the 
constraints of (1)-(11). Take any rni ,1,=   and any enk ,1,=  . We consider two 
cases depending on the value of kiy .   
    1.  0=kiy . From (3) we directly obtain 0kiz  and therefore 0=kiz .  
    2.  1=kiy . We consider two subcases:   
        - If for some ij R  we have 0=kjx  (a reagent is missing), then 0kiz  
from (4) and therefore 0=kiz . Similarly, if for some ij I  we have 1=kjx  (an inhibitor 
is present), then from (5) 0kiz  and therefore 0=kiz .  
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        - If for all ij R  we have 1=kjx  (all reagents present) and for all ij I  we 
have 0=kjx  (all inhibitors absent), then from (6) we obtain 1kiz  and therefore 
1=kiz .  
  
 Since the choice of i  and k  was arbitrary we have shown rnenZ {0,1} .  
 
 
Relaxation of non-input kjx  
  For the case that no loops are present in the pathway, we will argue that we 
can also use [0,1]kjx  for all species but the input species. In typical pathways the 
majority of species are noninput species. The formal definition of input species is  
 
Definition 1 (Input species) Species j  that are not products in any reaction, i.e.,  irnis jnj PT 1=:},{1,    are termed input species.  
 
 
Theorem 2  Suppose that the pathway proposed contains no loops. In (1)-(11) 
replacing rnenZ {0,1}  by rnenZ [0,1]  and {0,1}kjx  by [0,1]kjx  for all Tj  (for 
all non-input species) is an exact reformulation, in the sense that any feasible point in 
the new program is also feasible in the original program.  
 Note that input species cannot be relaxed, for otherwise {0,1}iz  would not be 
ensured. The proof idea is that because the potential pathway form a directed graph, 
we can proceed from the “top” to the “bottom”. In doing so we establish that both kjx  
and kiz  are forced to be integer. 
 
Proof. Take any snenX [0,1] , rny {0,1}  and rnenZ [0,1]  that satisfies the 
constraints of (1)-(11) and that also satisfies {0,1}kjx , for all Tj  (all input species 
are binary). 
In the proof of Theorem 2 we have established that if for a given reaction i  and 
experiment k , we have {0,1}kjx  for all iij IR   (all reagents and inhibitors are 
binary), then we also obtain {0,1}kiz . 
Take },{1, enk   (an arbitrary experiment) and },{1, snj   (an arbitrary 
species). We will argue that if {0,1}kiz  for all ir jni P :},{1,  (for all reactions for 
which the species is a product) then {0,1}kjy . There are essentially two cases: 
    1.  If for some ir jni P :},{1,  we have 1=kiz  then by (7) we obtain 
1kjx  and therefore 1=kjx .  
    2.  If for all ir jni P :},{1,  we have 0=kiz  then by (8) we obtain 0kjx  
and therefore 0=kjx .  
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It is clear that in the absence of loops the above two arguments propagate 
through the pathway. From an arbitrary species },{1, snj   we can traverse the 
graph in reverse direction and reach the input species in a finite number of steps (a 
reverse path). Due to the absence of loops, each species depends only on the species 
which are “further up” in the pathway. 
 
 
 
 
 
 
 
